Hungta Chen
AstraZeneca (United States)(US)
Publications by Year
Research Areas
Diabetes Treatment and Management, Chronic Obstructive Pulmonary Disease (COPD) Research, Diabetes Management and Research, Metabolism, Diabetes, and Cancer, Chronic Kidney Disease and Diabetes
Most-Cited Works
- → Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study(2013)539 cited
- → Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs(2018)459 cited
- → Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study(2012)312 cited
- → Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program)(2018)257 cited
- → Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes(2015)146 cited
- → SGLT-2 Inhibitors and Cardiovascular Risk(2018)129 cited
- → Prevalence of undiagnosed stage 3 chronic kidney disease in France, Germany, Italy, Japan and the USA: results from the multinational observational REVEAL-CKD study(2023)116 cited
- → Treatment of type 2 diabetes mellitus worldwide: Baseline patient characteristics in the global DISCOVER study(2019)98 cited
- → Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study(2020)92 cited
- → Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: The ENLIGHTEN study(2013)90 cited